Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 1, 2012, Pages 22-30

  Anderka, Marlene ^a   Mitchell, Allen A ^b   Louik, Carol ^b   Werler, Martha M ^b   Hernández Diaz, Sonia ^b,c   Rasmussen, Sonja A ^d  

^a MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

Hypospadias; Medications; National Birth Defects Prevention Study; Nausea and vomiting of pregnancy; Neural tube defects; Orofacial clefts

Indexed keywords

BELIDRAL; BISMUTH SALICYLATE; CALCIUM CARBONATE; CETIRIZINE; DIPHENHYDRAMINE; DOXYLAMINE; DOXYLAMINE PLUS PYRIDOXINE; METOCLOPRAMIDE; MYLANTA; ONDANSETRON; PROCHLORPERAZINE; PROMETHAZINE; PROTON PUMP INHIBITOR; PYRIDOXINE; RANITIDINE; STEROID;

ADULT; ARTICLE; BIRTH DEFECT; CEREBRAL PALSY; CLEFT LIP; CLEFT LIP PALATE; CLEFT PALATE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HYPOSPADIAS; INFANT; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NAUSEA AND VOMITING OF PREGNANCY; NEURAL TUBE DEFECT; PREGNANCY DISORDER; PRIORITY JOURNAL; RISK REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ADULT; CASE-CONTROL STUDIES; CLEFT LIP; CLEFT PALATE; FEMALE; HUMANS; HYPOSPADIAS; INFANT; INFANT, NEWBORN; MALE; NAUSEA; NEURAL TUBE DEFECTS; ONDANSETRON; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PROTON PUMP INHIBITORS; RISK FACTORS; STEROIDS; VOMITING; YOUNG ADULT;

EID: 84855944212     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.22865     Document Type: Article

References (36)

1. American College of Obstetrics and Gynecology. 2004. ACOG Practice Bulletin: nausea and vomiting of pregnancy. Obstet Gynecol 103: 803-814.
2. Arsenault MY, Lane CA, MacKinnon CJ, et al. 2002. The management of nausea and vomiting of pregnancy. J Obstet Gynaecol Can 24: 817-823.
3. Asker C, Wikner BN, Kallen B, et al. 2005. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 61: 899-906.
4. Black RA, Hill DA. 2003. Over-the-counter medications in pregnancy. Am Fam Physician 67: 2517-2524.
5. Boneva RS, Moore CA, Botto L, et al. 1999. Nausea during pregnancy and congenital health defects: a population-based case-control study. Am J Epi 149: 717-725.
6. Borrelli F, Capasso R, Aviello G, et al. 2005. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 105: 849-856.
7. Brent RL. 1995. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 9: 337-349.
8. Carmichael SL, Ma C, Werler MM, et al.; National Birth Defects Prevention Study. 2009. Maternal corticosteroid use and hypospadias. J Pediatr 155: 39-44.
9. Carmichael SL, Shaw GM, Ma C, et al.; National Birth Defects Prevention Study. 2007. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 197: 585.e1-e7.
10. Croen LA, Shaw GM, Lammer EJ, et al. 2000. Risk factors for cytogenetically normal holoprosencephaly in California: a population-based case-control study. Am J Med Genet 90: 320-325.
11. Dilts PV. 1992. Conception, implantation, placentation and embryology. In: The Merck manual of diagnosis and therapy: volume II-specialties. Rahway, NJ: Merck Research Laboratories, pp. 74-76.
12. Ebrahimi N, Maltepe C, Einarson A, et al. 2010. Optimal management of nausea and vomiting of pregnancy. Int J Womens Health 2: 241-248.
13. Einarson A, Maltepe C, Boskovic R, et al. 2007. Treatment of nausea and vomiting in pregnancy: an updated algorithm. Can Fam Physician 53: 2109-2111.
14. Einarson A, Maltepe C, Navioz Y, et al. 2004. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparison study. Br J Obstet Gynaecol 111: 940-943.
15. Furneaux EC, Langley-Evans AJ, Langley-Evans SC. 2001. Nausea and vomiting of pregnancy: endocrine basis and contribution to pregnancy outcome. Obstet Gynecol Surv 56: 775-782.
16. Genisca AE, Frias JL, Broussard CS, et al.; National Birth Defects Prevention Study. 2009. Orofacial clefts in the National Birth Defects Prevention Study, 1997-2004. Am J Med Genet A 149A: 1149-1158.
17. Gilboa SM, Strickland MJ, Olshan AF, et al.; National Birth Defects Prevention Study. 2009. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol l85: 137-150.
18. Gill SK, Einarson A. 2007. The safety of drugs for the treatment of nausea and vomiting of pregnancy. Expert Opin Drug Saf 6: 685-694.
19. Gill SK, O'Brien L, Einarson TR, et al. 2009. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 104: 1541-1545.
20. Kallen BA. 2001. Use of omeprazole during pregnancy-no hazard demonstrated in 955 infants exposed in pregnancy. Eur J Obstet Gynaecol Reprod Biol 96: 63-68.
21. Kallen B. 1998. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Brit J Obstet Gynaecol 105: 877-881.
22. Koren G, Clark S, Hankins GD, et al. 2010. Effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy: a randomized placebo controlled trial. Am J Obstet Gynecol 203: 571.e1-e7.
23. Khoury MJ, James LM, Erickson JD, et al. 1994. On the use of affected controls to address recall bias in case-control studies of birth defects. Teratology 49: 273-281.
24. Lalkin A, Loebstein R, Addis A, et al. 1998. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 179: 727-730.
25. Martinez-Frias ML, Rodriguez-Pinilla E, Prieto L, et al. 1997. Prenatal exposure to salicylates and gastroschsis: a case-control study. Teratology 56: 241-243.
26. Matok I, Gorodischer R, Koren G, et al. 2009. The safety of metoclopramide use in the first trimester of pregnancy. N Engl J Med 360: 2528-2535.
27. Mitchell AA. 2010. Proton pump inhibitors and birth defects-some reassurance, but more needed. N Engl J Med 363: 2161-2163.
28. Nikfar S, Abdollahi M, Mretti ME, et al. 2002. Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis. Dig Dis Sci 47: 1526-1529.
29. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. 2000. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385-392.
30. Pasternak B, Hviid A. 2010. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 363: 2114-2123.
31. Portnoi G, Chng LA, Karimi-Tabesh L, et al. 2003. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am J Obstet Gynecol 189: 1374-1377.
32. Pradat P, Robert-Gnansia E, Di Tanna GL, et al. 2003. Contributors to the MADRE database. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 67: 968-970.
33. Rasmussen SA, Olney RS, Holmes LB, et al. 2003. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67: 193-201.
34. Ruigomez A, Rodriguez LAG, Cattaruzzi C, et al. 1999. Use of cimetidine, omeprazole and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 150: 476-481.
35. Weigel RM. 2000. Nausea and vomiting in pregnancy and pregnancy outcome: an epidemiologic overview. In: Koren G, Bishai R, editors. Nausea and vomiting of pregnancy: state of the art. Vol 1. Toronto, Canada: Motherisk, pp 41-46.
36. Yoon PW, Rasmussen SA, Moore CA, et al. 2001. The National Birth Defects Prevention Study. Public Health Rep 116( Supp 1): 32-40.